Pre-made Vibecotamab biosimilar ( Bispecific Mixed mAb and scFv, anti-IL3RA;CD3E therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-619
Anti-IL3RA;CD3E therapeutic antibody (Pre-made Vibecotamab biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Vibecotamab (XmAb?14045) is a tumor-targeted antibody that contains both a CD123 binding domain and a cytotoxic T-cell binding domain (CD3) in a Phase 1 clinical trial for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IL3RA;CD3E therapeutic antibody (Pre-made Vibecotamab biosimilar,Bispecific Mixed mAb and scFv)|
|Format||Bispecific Mixed mAb and scFv|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;None|
|Conditions Active||Haematological malignancies|